Star Scientific (subsidiaries Star Tobacco and Star Pharma) Files 2007 Annual Report - a net loss of $41.5 million, as compared to a $12.3 million net

March 18, 2008 - Star Scientific (subsidiaries Star Tobacco and Star Pharma) Files 2007 Annual Report - a net loss of $41.5 million, as compared to a $12.3 million net loss for 2006.. Gross sales of the company's dissolvable smokeless tobacco products, Ariva(R) and Stonewall(R) increased to $0.7 million during 2007, a 41.9% increase from gross sales of $0.5 million in 2006. Net sales also increased by 23.2%, from $0.4 million in 2006 to $0.5 million in 2007. Total operating expenses increased $3.1 million, due primarily to $2.7 million in marketing and distribution costs for Ariva(R) and Stonewall(R). Ariva developed to give an adult smoker an alternative to cigarettes and Stonewall Hard Snuff develped for adult user of traditional snuff and chewing tobacco and smokers who consume more than one pack of cigarettes per day. Star markets and sells its smokeless tobacco products through field sales personnel, merchandisers and tobacco distributors in the U.S. If you go to the web site for Ariva and Stonewall not a word is mentioned about weaning a person from smoking. Star recommends that the lozenges be used as a substitute for smoking when you can't smoke. See related news briefs: Star Scientific gets Maine lawmakers to repeal a ban enacted last September 20, 2007 on the sale of a tobacco lozenge product known as hard snuff.. and New Life for Ariva®, Stonewall® Dissolvable Smokeless Tobacco Products... .